Sexual Dysfunction In Premenopausal Women Research Articles

Qualitative study exploring the experiences of sexual dysfunction in premenopausal women with type 1 diabetes

AbstractAimsTo explore the sexual experiences and interactions of women with type 1 diabetes to explicate an understanding of the impact of diabetes on women's sexual function. The study was conducted as part of a wider project to develop a patient‐reported outcome measure to assess sexual dysfunction (SD) in premenopausal women with type 1 diabetes.MethodsA qualitative study using face‐to‐face and virtual semi‐structured interviews was conducted with premenopausal women with type 1 diabetes who have had some difficulties related to sexual functioning. Participants were recruited from two National Health Services (NHS) sites in the UK and from social media platforms. The data were analysed to generate themes using Framework Analysis approach.ResultsEighteen women, aged 22–49, were interviewed (NHS sites n = 13; online n = 5). Five themes related to women experiences of SD were identified, these were; initiation of sexual activity, sexual confidence, sexual enjoyment, sexual engagement and sexual desire.ConclusionsSD in women with type 1 diabetes is a complex phenomenon impacting their experiences and quality of life. SD is related to multiple interacting biopsychosocial factors related to diabetes, including blood glucose levels, diabetes treatments, technologies and complications. A targeted measure of SD for women with type 1 diabetes specifically would allow for these factors to be assessed routinely in clinical care.

Prevalence and associated factors of sexual dysfunction in premenopausal women with type 1 diabetes: A systematic review and meta-analysis.

Sexual dysfunction (SD) in women with diabetes is a multifaceted complication driven by hormonal, neuropathic and psychosocial factors. It has been reported that the prevalence of SD is higher in women with type 1 diabetes compared to both women with type 2 diabetes and women without diabetes. However, prevalence estimates of SD in women with type 1 diabetes are variable, due to the heterogeneity of the conducted studies and the various confounding factors that are associated with SD. This review aimed to estimate the prevalence of SD in premenopausal women with type 1 diabetes compared to women without diabetes; consider current methods for measuring SD; and identify factors associated with SD in women with type 1 diabetes. A systematic review of the literature was conducted. Four electronic databases (Embase, MEDLINE, CINAHL, PsycINFO) were searched between 15 March and 29 April 2022, the search was updated on 4 February 2023 to identify studies that assessed SD in women with type 1 diabetes. The search yielded in 1104 articles; of these, 180 were assessed for eligibility. A meta-analysis of eight eligible studies revealed that the odds of experiencing SD is three times higher in women with type 1 diabetes compared to women without diabetes (OR = 3.8 95%CI 1.8-8.0, p < 0.001). The most commonly used measure of SD was the female sexual function index (FSFI); in three studies, this was combined with the female sexual distress scale (FSDS). Factors that have shown significant association with SD are depression, anxiety and duration of diabetes. This review has shown that SD is a significant issue for women with type 1 diabetes. These findings should encourage diabetes professionals and policymakers to give more attention to female SD (FSD) by incorporating it into care pathways and clinical guidelines.

Lower urinary tract symptoms in pre-menopausal women and its association with sexual dysfunction

Background: Sexual dysfunction (SD) is one of the common problems observed by premenopausal women and it frequently exists along with other associated lower urinary tract symptoms (LUTS).&#x0D; Aims and Objective: The present study was planned to evaluate the correlation between SD in pre-menopausal women with LUTS.&#x0D; Materials and Methods: This was a prospective observational study conducted between March 2018 to February 2019. All sexually active premenopausal women, who presented with complains of LUTS were enrolled in this study. All included patients were given two types of questionnaires (Bristol female lower urinary tract symptom [BFLUTS] and pelvic organ prolapse-urinary incontinence sexual function [PISQ-12]). These were for the assessment of LUTS and sexual function. Assessment of association between presence of LUTS and sexual dysfunction was done.&#x0D; Results: A total of 105 women were enrolled in the study. Their mean age was 43.70 years and BMI was 29.49. The total mean BFLUTS score recorded was 28.12. Their sub-dimension scores recorded for the filling, voiding, incontinence symptoms, sexual function and quality of life were 8.21, 34.32, 12.21, 4.49, and 10.65, respectively. Total mean score of PISQ-12 was 23.72 in all women and the mean values for the sub-dimension scores were 5.21 for the behavioural-emotive state, 11.78 for the physical state, and 6.2 for the partner-related state. There was Negative association observed between the total of PISQ-12 scores and total and sub-dimension of the BFLUTS scores (p&lt;0.01).&#x0D; Conclusion: This study observes the presence of LUTS in women with sexual dysfunction. LUTS directly or indirectly increase the sexual problems in premenopausal women. These results highlight the clinical importance of evaluating LUTS in premenopausal women with sexual dysfunction.

Investigation of Sexual Dysfunction in Premenopausal Women with Urinary Incontinence

Investigation of Sexual Dysfunction in Premenopausal Women with Urinary Incontinence

89P Tamoxifen versus aromatase inhibitors as adjuvant therapy in premenopausal women with hormone receptor-positive breast cancer: Effects on sexuality and the female reproductive system

The objective of this cross-sectional study is to compare the prevalence of sexual dysfunction in premenopausal women with breast cancer in Greece, who receive adjuvant endocrine therapy with either tamoxifen or aromatase inhibitors (AI), with or without ovarian function suppression (OFS). A second endpoint is to investigate and compare the incidence of genitourinary symptoms and conditions.

Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy.

Sexual dysfunction is common for breast cancer survivors. Premenopausal women with breast cancer are increasingly offered ovarian suppression and aromatase inhibitor (AI) therapy. We evaluated the association of menopausal status and treatment modalities on sexual dysfunction. We conducted a cross-sectional anonymous Female Sexual Function Index (FSFI) survey of breast cancer survivors between 2000 and 2016. Analysis utilized Kruskal-Wallis test for FSFI scores, Chi square, or Fisher's exact test for categorical data, and regression analysis for associations. Of 585 respondents, 278 (47.5%) had complete FSFI scores. Of these, 24 (8.6%) were premenopausal and 80 (28.8%) were pre/perimenopausal at survey completion. Median FSFI scores for premenopausal (31.2, interquartile range [IQR] 26.8-33.6) and pre/perimenopausal (29.2, IQR 25.9-32.2) were similar, whereas postmenopausal women (25.9, IQR 21.0-30.3) were significantly lower (p = 0.0007 and p = 0.0002, respectively). Premenopausal women were less likely to meet criteria for sexual dysfunction (FSFI score ≤ 26.55) than postmenopausal women (21 versus 55%, p < 0.0001, univariate analysis [odds ratio (OR) 0.32, 95% confidence interval (CI) 0.18-0.56]). Adjusting for treatment modality did not impact the significance (OR 0.43, 95% [CI] 0.23-0.80) but revealed that AIs independently are associated with sexual dysfunction (OR 2.41, 95% CI 1.32-4.40). The interaction between menopausal status and AIs was not significant (p = 0.24). Our study demonstrates that menopausal status is associated with sexual dysfunction in breast cancer patients and sexual dysfunction in premenopausal women is not impacted by treatment modality outside of aromatase inhibitor therapy. As more premenopausal patients are treated with ovarian suppression, these data may guide clinicians in counseling patients regarding sexual dysfunction expectations.

099 Flibanserin vs. Mini-Dose Trazodone for Female Sexual Dysfunction? A Challenge

Hypoactive Sexual Desire Disorder (HSDD) is the most common sexual dysfunction in pre-menopausal women, but post-menopausal women and women taking antidepressants or with breast or gynecologic cancer frequently have mixed or global sexual dysfunction. Flibanserin (FLI), the only drug approved for HSDD, is not licensed for post-menopausal use or for sexual arousal, orgasm, or sexual pain. Trazodone (TRZ) is unapproved for sexual dysfunction, but small trials and receptor data suggest value for various aspects. FLI and TRZ share some pharmacologic properties, including tolerability issues (CNS depression, drowsiness, dizziness, etc). This work is to compare experimental Results of relevance to efficacy and tolerability of FLI and TRZ for treating mixed or global sexual dysfunction in women. Conduct a literature review of human brain receptor properties, animal and clinical pharmacology, and relevant clinical trials of FLI and TRZ to compare the two. Table 1 summarizes Results. The additional receptor effects of TRZ (5HT2C, alpha) might increase sexual motivation and sexual arousal and thus improve lubrication, mitigating dyspareunia. Evidence for increased brain dopamine, and thus for facilitation of orgasm, is not directly available for TRZ but is positive (in animals) for FLI, yet this may be a general property of 1A agonists including TRZ, which equaled bupropion in improving orgasm (and desire) in a small clinical study. The H1 antagonism of TRZ, which may explain its more sedative properties, becomes relevant only with doses much larger than those required for 1A, 2A, and α1 receptor occupancy. With 100 mg FLI, 2A receptor effects apparently last for about 4 hours; 1A receptor effects, for >24 hours. With extended release TRZ, both receptors should be activated for 24 hours, even after a dose as low as 12 mg.

Patterns of female sexual dysfunction in premenopausal women with moderate to severe depression in Beni-Suef, Egypt

Abstract Background Depression is a disease of public health concern due to its high morbidity and mortality. Female sexual dysfunction is suggested to be associated with depression. The aim of this study is to investigate the prevalence of sexual disorders among premenopausal women with moderate to severe depression and detect any further correlates. Subjects and methods A total of 98 women with moderate to severe depression and attending the outpatient clinic in Beni-Suef General hospital participated in this study. A semi-structured questionnaire was used to collect socio-demographic and obstetric data. Then, all patients were asked to fill in the Arabic versions of Beck Depression Inventory to detect their level of depression and Female Sexual Function Index to assess the patterns of their sexual dysfunction. Results The mean age of the women was 32.1 ± 6.5 years. Of the 98 women, 50 (51%) had moderate depression and 48 (49%) had severe depression. Precisely, 77.6% of the women had sexual dysfunction. Dysfunctions in pain, lubrication and arousal were the most common reported problems 95.9%, 95.9% and 93.9%, respectively. Scores of depression inversely correlated with sexuality scores (p 0.05). Conclusion Problems in pain, lubrication and arousal were the most common patterns of sexual dysfunction in women with moderate to severe depression. Further research over the effect of certain interventional programs on female sexual dysfunction amongst depressed women should be considered.

The Phenomenon of Sexual Intercourse in Women Premenopausal In Makassar City

Sexual dysfunction in women is an important reproductive health issue as it relates to the survival of a woman's reproductive function and has a major impact on the harmony of marital relationships.&#x0D; The purpose of this study was to determine the effectiveness of Belle Vie Transfer Factor on Sexual Dysfunction in Premenopausal Women in Makassar City. The research method is qualitative with phenomenology approach. Based on the research, there were 6 people who consisted of 4 people &#x0D; The results showed that the sexual dysfunction experienced by the informant did not make the mother to stop consuming TF belle vie because according to the informant although in the use of TF belle vie sometimes make the passion decrease did not dampen his desire to use TF belle vie consumption TF belle vie used informant is in accordance with their wishes -something. There are also informants who say that TF belle vie is good for use especially premenopausal women, but basically, all informants using TF belle vie receive well despite complaints such as sexual dysfunction.&#x0D; It is expected that the health officer in charge to improve the performance and attention in giving counseling especially about the use of TF belle vie

Sexual Dysfunction in Premenopausal Women With Obstructive Sleep Apnea.

Sexual functions in the males with obstructive sleep apnea syndrome (OSAS) have been well investigated in the literature; however sexual functions in the premenopausal women with OSAS have been studied to a lesser extent. The study included 22 premenopausal women diagnosed as OSAS by the polysomnographic (PSG) evaluation. The control group included 13 premenopausal women suspected of sleep-relatedrespiratory disorder, but whose PSG tests were determined to be normal. Both groups were administered Epworth Sleep Scale (ESS), Beck Depression Scale (BDS), and Female Sexual Function Index (FSFI) questionnaire forms. Relations between disease parameters, and the total FSFI score, and scores of the six FSFI parameter were analyzed. The total FSFI score in the cases with OSAS, was determined to be significantly lower than that of the control subjects (P = .031). Scores of the desire, arousal, and orgasm were determined to be significantly lower inthe patient group, compared to control group (P = .034; P = .048; P = .039). The total FSFI scores, and scores of the desire, arousal, lubrication, orgasm, satisfaction and pain subscales in the cases did not correlate significantly with the apnea-hypopnea index (AHI), Non-Rapid Eye Movement 1 (NREM1)%, NREM2%, NREM3%, REM%, the time spent with saturation O2< 90%, minimum oxygen saturation (%), ESS scores, and BDS scores (all P > .05). Women with OSAS experience sexual dysfunction when compared with normal population. Clinical evaluation has to include also the evaluation of sexual life in women.

Non-alcoholic fatty liver disease as a risk factor for female sexual dysfunction in premenopausal women.

ObjectiveNon-alcoholic fatty liver disease (NAFLD) has become a common and important chronic liver disease worldwide. Previous studies have indicated that NAFLD has an adverse effect on the quality of life, but information is lacking about the impact of NAFLD on female sexual dysfunction. The aim of this study was to determine the association between NAFLD and female sexual dysfunction in premenopausal women.MethodsThis retrospective study consisted of premenopausal women who were sexually active and visited the outpatient clinic for a routine health check-up between January 2010 and December 2011. Based on the examination of the liver ultrasound scan, the study population was divided into 2 groups: cases with NAFLD and normal controls (cases without NAFLD). The female sexual function was compared between the two groups of cases. For the assessment of sexual function, a female sexual function index (FSFI) questionnaire was used.ResultsFour hundred seventy women were included, and the prevalence of NAFLD and female sexual dysfunction were 67/470 (14.3%) and 238/470 (50.6%), respectively. Cases with NAFLD had a lower total FSFI score and higher rate of female sexual dysfunction than the normal control [median score of total FSFI (interquartile range): 24.7 (21.9–27.8) in NAFLD vs. 26.7 (23.7–29.8) in normal control, p<0.005; the female sexual dysfunction: 64.2% in NAFLD vs. 48.4% in normal control, p<0.05]. This difference in female sexual dysfunction between the two groups remained significant after adjustment.ConclusionNAFLD is associated with female sexual dysfunction in premenopausal women.

Sexual dysfunction in premenopausal women could be related to hormonal profile

Female sexual dysfunction (FSD) is a public health problem that affects women's quality of life. Although the relationship between some hormones and the FSD has been described, it is not well established for all hormones. Therefore, the aim of our study was to evaluate the association between hormonal dysfunction and sexual dysfunction in premenopausal women. We performed a cross-sectional study with 60 patients with regular menstrual cycles, with age ranging from 18 to 44 years, with previous diagnosis of FSD. All patients were evaluated using the female sexual function index (FSFI) questionnaire and had the levels of total testosterone, prolactin (PRL), thyroid-releasing hormone and free testosterone index measured. Among the 60 patients, 43 (71.7%) were diagnosed with hypoactive sexual desire disorder (HSDD), 9 (15%) had anorgasmy and 8 (3.3%) had sexual pain dysfunction. Hormonal evaluation, demonstrated that 79.1% of patients with HSDD, 78.4% of patients with anorgasmy and 50% of patients with sexual pain dysfunction had female androgen insensitivity. We can conclude that there is an important association between low levels of total and free testosterone and FSD. This finding offers a new alternative for diagnosis and treatment of HSDD. Moreover, given the potential role of androgens in sexual function, randomized controlled trials with adequate long-term follow-up are essential to confirm its possible effect.

Vitamin D3 deficiency is associated with female sexual dysfunction in premenopausal women.

To assess female sexual functions in women who were affected by vitamin D3 deficiency. A total of 50 women with FSD and 58 healthy women controls were included in the study, according to the Female Sexual Function Index (FSFI) questionnaire using a 26.55 cutoff value. Detailed medical histories were obtained from all sexual active women, and all women were evaluated in terms of possible presence of depression with the Beck Depression Inventory (BDI). Serum 25-hydroxyvitamin D3, follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, total and free testosterone, estradiol, dehydroepiandrosterone-SO4 (DHEA-SO4), sex hormone-binding globulin (SHBG), free thyroxine (fT4), and thyroid-stimulating hormone (TSH) levels were measured. Mean age of premenopausal women was 34.9±6.3years. The level of serum 25-hydroxyvitamin D3 was significantly lower in women with FSD compared with the controls (15.9±8.4 and 26.3±11.7nmol/L, respectively). Desire (p=0.0001), arousal (p=0.0001), lubrication (p=0.002), orgasm (p=0.0001), satisfaction (p=0.018), and pain (p=0.010) domain scores were also correlated with the levels of serum 25-hydroxyvitamin D3. The BDI score showed a significant negative correlation with the total FSFI score (r=-0.492, p=0.0001). The FSFI score not showed a significant correlation with the hormones (p>0.05). There is a relationship with FSD and deficiency of vitamin D3. Also, increased depressive symptoms were associated with FSD.

Effect of Surgery and Adjuvant Therapy in Reproductive and Sexual Dysfunction in Pre-menopausal Women with Breast Cancer

Breast cancer is one of the most common cancers in women. Approximately twenty five percent breast cancer occurs during the reproductive and perimenopausal years. Surgery is the primary treatment of breast cancer. In addition, based on stage and biology of the disease, chemotherapy, radiation, endocrine therapy and biologics are recommended to reduce recurrence and cancer-related mortality. Although survival rates of women with breast cancer has significantly improved, the potential late adverse effects of adjuvant treatment and their impact on quality of life of breast cancer survivors have become increasingly important. Among premenopausal women with breast cancer, management of sexual dysfunction and fertility presents a challenge. The principal mechanisms that systemic therapy affect sexual function and fertility in women with breast cancer is ovarian suppression. In addition, cancer therapy alters anatomy and causes mucosal or skin changes that result in impaired sexual and reproductive health. In this article we review the effect of surgery and adjuvant therapy on reproductive and sexual health of young breast cancer survivors and briefly discuss various treatment options.

PD04-03: Sexual Dysfunction in Premenopausal Women with Breast Cancer: Prevalence and Severity.

Abstract Background: Sexual dysfunction is reported after chemotherapy and endocrine therapies. However, the prevalence and severity of sexual dysfunction in premenopausal women undergoing therapy for both local and metastatic disease is not well defined. This study was performed in order to understand the impact of contemporary breast cancer treatment on the prevalence and severity of sexual health in premenopausal women. Methods: We developed a survey that includes a previously validated questionnaire, the Female Sexual Function Index (FSFI), as well as an established measure of health-related quality of life (the EuroQol EQ-5D), and disease-specific items to characterize sexual dysfunction and its causes based on literature review and expert consultations. Anonymous administration of the surveys was conducted in outpatient clinic waiting areas of the Breast Cancer Center at Memorial Sloan-Kettering Cancer Center (MSKCC), under an IRB waiver of consent. Results: 372 consecutively approached premenopausal women with breast cancer of any stage, undergoing treatment were each queried once. The mean age was 47. 87% reported current or past hormonal treatment, and 86% reported current or past chemotherapy (76% adjuvant; 24% for metastatic disease). Sexual dysfunction attributed to breast cancer or its treatment, defined as an FSFI score &amp;lt;26, was reported by 75% of respondents with a mean score of 16.3. Among these women, 79% of patients considered their sexual symptoms to be bothersome, with 51% noting moderate or severe levels of bother (score &amp;gt;=5/10). In a multivariate analysis, metastatic disease, development of amenorrhea from cancer treatment, antidepressant use and poorer overall health were each significantly associated with worse FSFI scores. Lower FSFI scores were also significantly associated with worse health-related quality of life. Conclusion: Sexual dysfunction is prevalent in premenopausal women treated for breast cancer and should be discussed with patients as a potential adverse effect of therapy. Assessment of sexual symptoms throughout treatment and beyond may facilitate the use of potential interventions such as lubricants, dilators, treatment modification and counseling. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr PD04-03.

Sexual Dysfunction in Women With the Metabolic Syndrome

Female sexual dysfunction is a largely uninvestigated, yet significant, public health problem, with 43% of women complaining of at least one sexual problem (1). Despite the high prevalence, which appears to surpass that of male sexual dysfunction, only recently has there been some focus on the sexual problems of women. We assessed the prevalence of sexual dysfunction in premenopausal women with the metabolic syndrome as compared with the general female population. Premenopausal women ( n = 100) were enrolled if they had three …